Table 3.
Sensitivity, specificity, positive predictive value, and negative predictive value of PSAD ≥ 0.08 ng/mL/cc for clinically significant prostate cancer in 2162 subjects with varying disease prevalence.
| Hypothetical Population (n = 2162) with 50% Disease Prevalence | ||||
| Disease Positive | Disease Negative | Row Total | Predictive Values | |
| PSAD Positive | 1059 | 908 | 1967 | (↑) PPV = 1059/1967 (54%) |
| PSAD Negative | 22 | 173 | 195 | (↓) NPV = 173/195 (89%) |
| Column Total | 1081 | 1081 | ||
| SN = 1059/1081 (98%) | SP = 173/1081 (16%) | |||
| Actual Study Population (23% Disease Prevalence, 98% Sensitivity, 16% Specificity) (n = 2162) | ||||
| Disease Positive | Disease Negative | Row Total | Predictive Values | |
| PSAD Positive | 489 | 1400 | 1889 | PPV = 489/1889 (26%) |
| PSAD Negative | 10 | 263 | 273 | NPV = 263/273 (96%) |
| Column Total | 499 | 1663 | ||
| SN = 489/499 (98%) | SP = 263/1663 (16%) | |||
| Hypothetical Population (n = 2162) with 10% Disease Prevalence | ||||
| Disease Positive | Disease Negative | Row Total | Predictive Values | |
| PSAD Postive | 212 | 1635 | 1847 | (↓) PPV = 212/1847 (11%) |
| PSAD Negative | 4 | 311 | 315 | (↑) NPV = 311/315 (99%) |
| Column Total | 216 | 1946 | ||
| SN = 212/216 (98%) | SP = 311/1946 (16%) | |||
Note: Abbreviations—NPV, negative predictive value; PPV, positive predictive value; PSAD, prostate-specific antigen density; SN, sensitivity; SP, specificity.